The role of genetics and epigenetics in rheumatic diseases: are they really a target to be aimed at?

Masaru Kato*, Shinsuke Yasuda, Tatsuya Atsumi

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

To date, numerous genetic and epigenetic studies have been performed and provided a crucial step forward in our understanding of the pathogenesis of rheumatic diseases. However, most of the recent advances in the treatment of rheumatic diseases including biological therapies are not based on or even discrepant from these genetic and epigenetic findings. For example, tumor necrosis factor inhibitors are quite successful in the treatment of rheumatoid arthritis (RA), Behçet’s disease (BD), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) but not in that of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren’s syndrome (SS) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV), conversely, RA shares genetic backgrounds more with SLE, SSc, SS and AAV than BD, AS and PsA. In this review, we briefly highlight the findings from recent genetic and epigenetic studies and discuss what needs to be studied to provide a novel, more efficacious management of rheumatic diseases.

Original languageEnglish
Pages (from-to)1333-1338
Number of pages6
JournalRheumatology International
Volume38
Issue number8
DOIs
StatePublished - 2018/08/01

Keywords

  • Epigenetics
  • GWAS
  • Genetics
  • Rheumatic diseases

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'The role of genetics and epigenetics in rheumatic diseases: are they really a target to be aimed at?'. Together they form a unique fingerprint.

Cite this